An interventional study of AI-video laryngoscopy (AIVL) and Conventional Video Laryngoscope (VL) in Critically Ill Patients Requiring Mechanical Ventilation, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Not applicable, Interventional, and Treatment
The investigators are developing a video laryngoscope equipped with artificial intelligence technology to enable automatic identification of key airway anatomical structures and real-time guidance during intubation, with the aim of improving the success rate and efficiency of endotracheal intubation in emergency settings.
Second Affiliated Hospital, Zhejiang University, School of Medicine is the lead sponsor of 99 studies on the registry; 67 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to this arm (n=60) will undergo the first endotracheal intubation attempt using a conventional video laryngoscope (VL), without AI-assisted anatomical identification or intubation guidance.
Device: Conventional Video Laryngoscope (VL)
Participants randomized to this arm (n=60) will undergo the first endotracheal intubation attempt using an AI-assisted video laryngoscope (AIVL), which provides real-time identification of airway anatomical structures and intubation guidance. Operators will receive standardized training on the device controls, guidance interface, and image display before use. Operators may decide whether to follow the AI guidance.
Device: AI-video laryngoscopy (AIVL)
When using the AIVL for the first attempt at laryngoscopy intubation, the operator shall receive pre-procedural training, which primarily covers the functional buttons, the prompt interface, and image display.
A conventional video laryngoscope will be used for the first endotracheal intubation attempt. The device displays the airway image without AI-assisted identification of anatomical structures or real-time AI intubation guidance.
First-pass intubation success rate
Proportion of participants with successful endotracheal tube placement on the first laryngoscopic attempt, confirmed by end-tidal carbon dioxide monitoring.
Time frame: The time from enrollment to completion of intubation (usually within 10 minutes).
Intubation time
Time in seconds from insertion of the laryngoscope into the oral cavity until the endotracheal tube passes through the glottis.
Time frame: The time from enrollment to completion of intubation (usually within 10 minutes).
Severe complications occurring within 2 minutes after intubation were defined as severe hypoxemia (peripheral SpO₂ <80%), severe hypotension (systolic blood pressure <65 mmHg), initiation of vasoactive agents, cardiac arrest, or death.
Time frame: From enrollment to the 2 minutes after intubation
AI recall
True-positive anatomical detections divided by true-positive plus false-negative detections, assessed against reference annotations.
Time frame: The time from enrollment to completion of intubation (usually within 10 minutes).
Duration of mechanical ventilation
Duration of mechanical ventilation, measured in days.
Time frame: From enrollment to the end of treatment at 8 weeks
28-day all-cause mortality
Proportion of participants who die from any cause within 28 days after enrollment.
Time frame: From enrollment through day 28.
ICU length of stay
Duration of intensive care unit stay, measured in days.
Time frame: From enrollment through the end of treatment, up to 8 weeks.
Total hospital length of stay
Total duration of hospitalization, measured in days.
Time frame: From enrollment through the end of treatment, up to 8 weeks.
AI precision
True-positive anatomical detections divided by true-positive plus false-positive detections, assessed against reference annotations.
Time frame: Video acquired from enrollment to completion of intubation, usually within 10 minutes.
AI specificity
True-negative assessments divided by true-negative plus false-positive assessments, assessed against reference annotations.
Time frame: Video acquired from enrollment to completion of intubation, usually within 10 minutes.
AI F1 score
Harmonic mean of precision and recall: 2 x precision x recall / (precision + recall).
Time frame: Video acquired from enrollment to completion of intubation, usually within 10 minutes.
Mean average precision (mAP)
Mean of average precision across the evaluated anatomical classes against reference annotations.
Time frame: Video acquired from enrollment to completion of intubation, usually within 10 minutes.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Second Affiliated Hospital, Zhejiang University, School of Medicine